Q/C TECHNOLOGIES INC (QCLS) Fundamental Analysis & Valuation

NASDAQ:QCLS • US62856X3008

Current stock price

3.45 USD
+0.21 (+6.48%)
At close:
3.42 USD
-0.03 (-0.87%)
After Hours:

This QCLS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. QCLS Profitability Analysis

1.1 Basic Checks

  • In the past year QCLS has reported negative net income.
  • QCLS had a negative operating cash flow in the past year.
  • In the past 5 years QCLS always reported negative net income.
  • In the past 5 years QCLS always reported negative operating cash flow.
QCLS Yearly Net Income VS EBIT VS OCF VS FCFQCLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • QCLS has a Return On Assets of -31.05%. This is comparable to the rest of the industry: QCLS outperforms 50.52% of its industry peers.
  • QCLS has a Return On Equity of -54.23%. This is comparable to the rest of the industry: QCLS outperforms 49.48% of its industry peers.
Industry RankSector Rank
ROA -31.05%
ROE -54.23%
ROIC N/A
ROA(3y)-86.48%
ROA(5y)-85.52%
ROE(3y)-117.42%
ROE(5y)-105.9%
ROIC(3y)N/A
ROIC(5y)N/A
QCLS Yearly ROA, ROE, ROICQCLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • QCLS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QCLS Yearly Profit, Operating, Gross MarginsQCLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

5

2. QCLS Health Analysis

2.1 Basic Checks

  • QCLS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for QCLS has been increased compared to 5 years ago.
  • There is no outstanding debt for QCLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
QCLS Yearly Shares OutstandingQCLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
QCLS Yearly Total Debt VS Total AssetsQCLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -5.25, we must say that QCLS is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -5.25, QCLS is doing worse than 63.54% of the companies in the same industry.
  • QCLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.25
ROIC/WACCN/A
WACCN/A
QCLS Yearly LT Debt VS Equity VS FCFQCLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • QCLS has a Current Ratio of 1.71. This is a normal value and indicates that QCLS is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.71, QCLS is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.71 indicates that QCLS should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.71, QCLS perfoms like the industry average, outperforming 41.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.71
QCLS Yearly Current Assets VS Current LiabilitesQCLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

0

3. QCLS Growth Analysis

3.1 Past

  • QCLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.50%, which is quite impressive.
EPS 1Y (TTM)87.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QCLS Yearly Revenue VS EstimatesQCLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 1M 2M 3M 4M 5M
QCLS Yearly EPS VS EstimatesQCLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 -500K -1M

0

4. QCLS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for QCLS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QCLS Price Earnings VS Forward Price EarningsQCLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QCLS Per share dataQCLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. QCLS Dividend Analysis

5.1 Amount

  • No dividends for QCLS!.
Industry RankSector Rank
Dividend Yield 0%

QCLS Fundamentals: All Metrics, Ratios and Statistics

Q/C TECHNOLOGIES INC

NASDAQ:QCLS (3/31/2026, 8:02:42 PM)

After market: 3.42 -0.03 (-0.87%)

3.45

+0.21 (+6.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-17
Earnings (Next)04-09
Inst Owners18.07%
Inst Owner Change4375.05%
Ins Owners10.6%
Ins Owner Change45.46%
Market Cap14.39M
Revenue(TTM)N/A
Net Income(TTM)-11.56M
AnalystsN/A
Price TargetN/A
Short Float %39.91%
Short Ratio1.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.5
Dividend Growth(5Y)N/A
DP-11.74%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-165.47
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.59
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS0
BVpS5.11
TBVpS-0.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.05%
ROE -54.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-86.48%
ROA(5y)-85.52%
ROE(3y)-117.42%
ROE(5y)-105.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.71
Altman-Z -5.25
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.74%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.14%
OCF growth 3YN/A
OCF growth 5YN/A

Q/C TECHNOLOGIES INC / QCLS Fundamental Analysis FAQ

What is the fundamental rating for QCLS stock?

ChartMill assigns a fundamental rating of 2 / 10 to QCLS.


Can you provide the valuation status for Q/C TECHNOLOGIES INC?

ChartMill assigns a valuation rating of 0 / 10 to Q/C TECHNOLOGIES INC (QCLS). This can be considered as Overvalued.


How profitable is Q/C TECHNOLOGIES INC (QCLS) stock?

Q/C TECHNOLOGIES INC (QCLS) has a profitability rating of 1 / 10.


Can you provide the financial health for QCLS stock?

The financial health rating of Q/C TECHNOLOGIES INC (QCLS) is 5 / 10.